GlassScriptPhysician profile
Lisa M Gruson
NPI 1538118435
$4,641.90
in general payments reported to CMS, 2019-2025
27 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $218 · 2021: $363 · 2022: $994 · 2023: $1,058 · 2024: $872 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566 · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.38 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.89 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $563.08 | 2019-2025 | Winlevi |
| Janssen Biotech, INC. | $521.89 | 2019-2024 | Tremfya |
| Dermavant Sciences, INC. | $461.61 | 2023-2024 | Vtama |
| Genzyme Corporation | $304.92 | 2019-2025 | |
| Leo Pharma INC. | $225.71 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $215.55 | 2020-2025 | |
| Amgen INC. | $212.50 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $137.93 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $109.67 | 2019-2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $106.45 | 2022-2024 | Aklief |
| Encore Dermatology INC. | $102.68 | 2019 | |
| Mayne Pharma Commercial LLC | $87.90 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $87.53 | 2019-2025 | Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $60.13 | 2022-2023 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $53.67 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $53.05 | 2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $50.59 | 2021 | |
| Incyte Corporation | $47.15 | 2022-2025 | Opzelura |
| Pfizer INC. | $45.92 | 2023 | |
| Allergan, INC. | $45.89 | 2021 | |
| Springworks Therapeutics, INC. | $29.08 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.08 | 2023 | Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $19.12 | 2021 | |
| Epi Health, LLC | $17.48 | 2021 | |
| Almirall LLC | $17.47 | 2019 | |
| Journey Medical Corporation | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Gruson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.